Metabolism of psychotropic drugs: pharmacological and clinical relevance.

Cytochrome P-450 (CYP) catalyzes phase I metabolic reactions of psychotropic drugs. The main isoenzymes responsible for their biotransformation are CYP1A2, CYP2D6, CYP3A4 and these of the subfamily CYP2C. The majority of metabolites of psychotropic drugs are biologically active. Some of them retain pharmacological properties of parent compounds (eg. selective serotonin reuptake inhibitors, risperidone, carbamazepine, benzodiazepines), but others display quite different (eg. amitriptyline, buspirone) or even opposite (trazodone) profiles. They are present in vivo in concentrations high enough to contribute to pharmacological and clinical effects of the administrated drugs. Active metabolites of psychotropics are also characterized by pharmacokinetic properties different from their parent compounds, e.g. half-life time, plasma protein binding, blood-brain-barrier penetration, the cerebrospinal fluid (CSF) protein binding and tissue binding. These properties lead, in turn, to differences in the brain/plasma and the CSF/plasma concentration ratios between a drug and its metabolites. Therefore studies relating a pharmacological or therapeutic response of psychotropic drug to its plasma concentrations should not disregard the presence of its active metabolites, considering their distinct pharmacological and pharmacokinetic properties. With regard to a low therapeutic index of psychotropics, interindividual differences in the rate of their metabolism, genetic polymorphism of their main metabolic pathways and metabolic interactions in clinical drug combinations, the phenotyping of patients at the beginning of therapy and a control of drug concentrations (and its active metabolites) at a steady state and during coadministration of another drug, may increase the efficiency and safety of the pharmacotherapy of psychiatric disorders.